Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.

Leukemia·2026
Same author

Recent advances in AML with mutated NPM1.

International journal of hematology·2024
Same author

Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia.

Scientific reports·2024
Same author

Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells.

Nature communications·2022
Same author

Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood advances·2021
Same author

Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.

PloS one·2018

Related Experiment Video

Updated: Jun 11, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

37

Recent progress in AML with recurrent genetic abnormalities.

Yuichi Ishikawa1

  • 1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-ku, Nagoya, 466-8550, Japan. yishikaw@med.nagoya-u.ac.jp.

International Journal of Hematology
|October 1, 2024
PubMed
Summary
This summary is machine-generated.

Favorable-risk acute myeloid leukemia (AML) requires better risk stratification due to relapses. Research explores molecular abnormalities and FLT3 mutations to improve treatment strategies for AML patients.

Keywords:
FLT3 mutationAMLFavorable riskMolecular targeted therapyRecurrent genetic abnormalities

More Related Videos

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.5K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.2K

Related Experiment Videos

Last Updated: Jun 11, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

37
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.5K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.2K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is a complex disease with diverse molecular features influencing patient outcomes.
  • Current prognostic models for AML rely on chromosomal and genetic abnormalities, but challenges remain, particularly in favorable-risk groups.
  • Favorable-risk AML, including cases with NPM1 or CEBPA mutations, still experiences relapse in a significant proportion of patients.

Purpose of the Study:

  • To address the need for improved risk stratification in favorable-risk AML.
  • To investigate the role of molecular abnormalities, including FLT3 mutations, in AML pathogenesis and prognosis.
  • To discuss current trends and challenges in targeted therapies for AML.

Main Methods:

  • Review of current literature on molecular abnormalities in AML.
  • Analysis of prognostic impact of genetic mutations like NPM1, CEBPA, and FLT3.
  • Discussion of targeted therapy development and resistance mechanisms in AML.

Main Results:

  • NPM1 and CEBPA mutations define a favorable-risk group in cytogenetically normal AML, yet relapse occurs in ~40% of patients.
  • FLT3 mutations are common in favorable-risk AML subtypes, but their prognostic significance is debated.
  • Targeted therapies have emerged as effective treatments, but resistance poses a significant challenge.

Conclusions:

  • Further risk stratification based on molecular profiles is crucial for optimizing treatment in favorable-risk AML.
  • Understanding molecular abnormalities and developing novel targeted therapies are key to improving AML patient outcomes.
  • Addressing resistance to targeted therapies is essential for long-term treatment success in AML.